Key result
SGLT2 inhibitors reduce mortality, HF hospitalizations, and renal progression in T2D with cardiovascular disease.
Why the study?
Sodium-glucose co-transporter 2 inhibitors reduce mortality and heart failure hospitalisation in type 2 diabetes with cardiovascular disease but have adverse effects related to their mechanism of action.
Do SGLT2 inhibitors improve cardiovascular and renal outcomes and what are their adverse effects in patients with type 2 diabetes?
Do SGLT2 inhibitors improve cardiovascular and renal outcomes and what are their adverse effects in patients with type 2 diabetes?
SGLT2 inhibitors provide substantial cardiovascular and renoprotective benefits in type 2 diabetes, but clinicians must manage risks like genital infections and diabetic ketoacidosis.
Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to the mechanism of action. These include polyuria and intravascular volume depletion from osmotic diuresis, and genitourinary infections from glycosuria. Ketoacidosis is a rare adverse effect The glucose-lowering efficacy of sodium-glucose co-transporter 2 inhibitors decreases with increasing renal impairment
No takes yet. Share an insight, caveat, or question.
Chesterman et al. (2020) conducted a review in Type 2 diabetes and cardiovascular disease. SGLT2 inhibitors was evaluated. SGLT2 inhibitors reduce all-cause mortality, cardiovascular mortality, heart failure hospitalizations, and renal disease progression in patients with type 2 diabetes and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: